M D Pescovitz

Summary

Affiliation: Indiana University
Country: USA

Publications

  1. ncbi Prospective observational study of sirolimus as primary immunosuppression after renal transplantation
    Mark D Pescovitz
    Indiana University School of Medicine, Indianapolis, IN, USA
    Transplantation 88:1010-8. 2009
  2. ncbi Formulary considerations for drugs used to prevent cytomegalovirus disease
    Mark D Pescovitz
    Organ Transplant Program, Indiana University Medical Center, Indianapolis, IN, USA
    Am J Health Syst Pharm 60:S17-21. 2003
  3. ncbi Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation
    Mark D Pescovitz
    Indiana University, Indianapolis, IN 46202, USA
    Clin Transplant 17:511-7. 2003
  4. ncbi Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients
    M D Pescovitz
    Department of Surgery, Indiana University, Indianapolis, Indiana 46202 5124, USA
    Transpl Infect Dis 12:195-203. 2010
  5. ncbi The use of rituximab, anti-CD20 monoclonal antibody, in pediatric transplantation
    Mark D Pescovitz
    Department of Surgery, UH 4258, Indiana University Medical Center, 550 N University Boulevard, Indianapolis, IN 46202, USA
    Pediatr Transplant 8:9-21. 2004
  6. ncbi Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action
    M D Pescovitz
    Department of Surgery, Indiana University, Indianapolis, IN, USA
    Am J Transplant 6:859-66. 2006
  7. ncbi A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients
    M D Pescovitz
    Department of Surgery, Indiana University, Indianapolis, IN, USA
    Am J Transplant 9:2324-30. 2009
  8. ncbi Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients
    Mark D Pescovitz
    Department of Surgery, Indiana University, Indianapolis, Indiana 46202, USA
    Br J Clin Pharmacol 64:758-71. 2007
  9. ncbi Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients
    Mark D Pescovitz
    Department of Surgery, Indiana University, Indianapolis, IN 46202, USA
    Pediatr Transplant 12:447-55. 2008
  10. ncbi Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation
    M D Pescovitz
    Department of Surgery, Indiana University, Indianapolis, Indiana 46202 5253, USA
    Transplant Proc 39:3111-6. 2007

Detail Information

Publications67

  1. ncbi Prospective observational study of sirolimus as primary immunosuppression after renal transplantation
    Mark D Pescovitz
    Indiana University School of Medicine, Indianapolis, IN, USA
    Transplantation 88:1010-8. 2009
    ..CONCLUSIONS.: SRL is most commonly used in combination with mycophenolate mofetil, CsA, or TAC. BCAR was least common in subjects receiving SRL+TAC, but other outcomes seemed comparable between the treatment regimens in routine practice...
  2. ncbi Formulary considerations for drugs used to prevent cytomegalovirus disease
    Mark D Pescovitz
    Organ Transplant Program, Indiana University Medical Center, Indianapolis, IN, USA
    Am J Health Syst Pharm 60:S17-21. 2003
    ..The single daily dose and lack of resistance to valganciclovir are advantages over oral ganciclovir, which requires three daily doses and can result in the development of resistance...
  3. ncbi Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation
    Mark D Pescovitz
    Indiana University, Indianapolis, IN 46202, USA
    Clin Transplant 17:511-7. 2003
    ..The coadministration of daclizumab did not result in a pharmacokinetic interaction with MPA, the active metabolite of MMF...
  4. ncbi Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients
    M D Pescovitz
    Department of Surgery, Indiana University, Indianapolis, Indiana 46202 5124, USA
    Transpl Infect Dis 12:195-203. 2010
    ..A dosing algorithm based on BSA and CrCL should be tested in future studies...
  5. ncbi The use of rituximab, anti-CD20 monoclonal antibody, in pediatric transplantation
    Mark D Pescovitz
    Department of Surgery, UH 4258, Indiana University Medical Center, 550 N University Boulevard, Indianapolis, IN 46202, USA
    Pediatr Transplant 8:9-21. 2004
    ..There are few data on its use in children. This paper reviews the use of rituximab in these disease states and provides hypotheses for its mode of action...
  6. ncbi Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action
    M D Pescovitz
    Department of Surgery, Indiana University, Indianapolis, IN, USA
    Am J Transplant 6:859-66. 2006
    ..A need for controlled clinical trials is clearly indicated before the widespread use of this drug in transplant...
  7. ncbi A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients
    M D Pescovitz
    Department of Surgery, Indiana University, Indianapolis, IN, USA
    Am J Transplant 9:2324-30. 2009
    ..Routine therapeutic drug monitoring of tacrolimus blood concentrations should be included both at initiation and completion of maribavir treatment...
  8. ncbi Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients
    Mark D Pescovitz
    Department of Surgery, Indiana University, Indianapolis, Indiana 46202, USA
    Br J Clin Pharmacol 64:758-71. 2007
    ..Safety and efficacy (biopsy-proven acute rejection (BPAR)) were also assessed...
  9. ncbi Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients
    Mark D Pescovitz
    Department of Surgery, Indiana University, Indianapolis, IN 46202, USA
    Pediatr Transplant 12:447-55. 2008
    ..5% and 16.7%, respectively. This study shows that adding daclizumab at 1 mg/kg to standard immunosuppressive therapy provides safe and effective IL-2R blockade...
  10. ncbi Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation
    M D Pescovitz
    Department of Surgery, Indiana University, Indianapolis, Indiana 46202 5253, USA
    Transplant Proc 39:3111-6. 2007
    ..With the demonstration of bioequivalence and no differences in the incidence of adverse effects, it will be possible to interchangeably use the oral formulation...
  11. ncbi Valganciclovir: recent progress
    M D Pescovitz
    Department of Surgery and Department of Microbiology Immunology Indiana University, Indianapolis, IN, USA
    Am J Transplant 10:1359-64. 2010
    ..Other trials clearly show that extended therapy provides added benefit, the drug is safe and an appropriate dose has been identified in children and oral therapy of CMV disease is effective...
  12. ncbi Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients
    Mark D Pescovitz
    Indiana University, Indianapolis, IN, USA
    Am J Transplant 3:1581-6. 2003
    ..196) nor differences between diabetics and nondiabetics. This study demonstrates that dosing requirement for MMF in AA and Caucasians is unlikely to be related to different exposures to MPA...
  13. ncbi Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients
    M D Pescovitz
    Transplantation Section, Department of Surgery, and Department of Microbiology Immunology, Indiana University, Indianapolis, Indiana 42602, USA
    Antimicrob Agents Chemother 44:2811-5. 2000
    ..Oral VGC delivers systemic GCV exposure equivalent to that of standard oral GCV (at 450 mg) or i.v. GCV (at 900 mg of VGC). VGC has promise for effective CMV prophylaxis or treatment with once-daily oral dosing in transplant recipients...
  14. ncbi Oral ganciclovir and pharmacokinetics of valganciclovir in liver transplant recipients
    M D Pescovitz
    Surgery and Microbiology Immunology, Indiana University, Indianapolis 46202, USA
    Transpl Infect Dis 1:31-4. 1999
    ..This drug may improve prophylactic efficacy in the high-risk CMV seropositive donor/seronegative negative recipient transplant groups and may also allow treatment of established CMV disease with an oral formulation...
  15. ncbi B cells: a rational target in alloantibody-mediated solid organ transplantation rejection
    Mark D Pescovitz
    Department of Surgery, Indiana University, Indianapolis, IN 46202, USA
    Clin Transplant 20:48-54. 2006
    ..Promising results suggest that this strategy warrants further investigation in larger controlled studies...
  16. ncbi Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients
    M D Pescovitz
    Departments of Surgery, Microbiology Immunology, and Medicine, Indiana University, Indianapolis, IN 46202, USA
    Am J Kidney Dis 38:S16-21. 2001
    ..This paper reviews the results of clinical trials that have investigated these new approaches to immunosuppression in renal transplant recipients...
  17. ncbi Immunosuppressive therapy and post-transplantation diarrhea
    M D Pescovitz
    Department of Surgery, Indiana University, Indianapolis, USA
    Clin Transplant 15:23-8. 2001
    ..This review considers each of these factors in assessing the overall incidence of post-transplantation diarrhea for the various immunosuppressive medications currently in use...
  18. ncbi Daclizumab: humanized monoclonal antibody to the interleukin-2 receptor
    Mark D Pescovitz
    Indiana University, UH 4601, 550 N University Blvd, Indianapolis, IN 46202, USA
    Expert Rev Clin Immunol 1:337-44. 2005
    ..A new subcutaneous formulation is being developed to facilitate chronic dosing in these autoimmune diseases...
  19. ncbi Two-hour post-dose cyclosporine level is a better predictor than trough level of acute rejection of renal allografts
    Mark D Pescovitz
    Department of Surgery, Transplantation Section and Microbiology Immunology, Indiana University, Indianapolis, IN, USA
    Clin Transplant 16:378-82. 2002
    ..The CyA C2 levels predict the frequency of rejection postrenal transplant. Target C2 levels are in the range of 1500 ng/dL...
  20. ncbi Use of antibody induction in pediatric renal transplantation
    Mark D Pescovitz
    Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Curr Opin Organ Transplant 13:495-9. 2008
    ..The present review provides an update on the recent literature documenting the use of antibody induction in pediatric transplantation...
  21. ncbi The addition of sirolimus to cyclosporine and steroids inhibits the anti-equine antibody response in renal transplant recipients treated with antithymocyte globulin
    Mark D Pescovitz
    Departments of Surgery and Microbiology Immunology, Indiana University, Indianapolis, IN 46202, USA
    Am J Transplant 3:497-500. 2003
    ..Compared to AZA, sirolimus, when given in combination with cyclosporine A, significantly reduced anti-equine antibody formation to a degree similar to MMF...
  22. ncbi A cost too high to bear? Prophylaxis versus preemptive therapy to prevent post-transplantation cytomegalovirus
    M D Pescovitz
    Indiana University Medical Center, Department of Surgery, Indianapolis, Indiana 46202, USA
    Kidney Int 72:912-3. 2007
    ..While the overall cost of the two modalities is similar, current literature suggests that prophylaxis has an advantage in avoiding secondary effects of CMV. Randomized comparative trials are imperative...
  23. ncbi In vitro monitoring of in vivo development of human anti-thymoglobulin antibodies by ELISA
    B K Book
    Indiana University School of Medicine, Department of Surgery, Indianapolis, Indiana, USA
    Transplant Proc 38:2869-71. 2006
    ..Formation of such antixenoantibodies can have a negative impact on treatment response and hence warrant monitoring...
  24. ncbi Follow-up experience using histidine-tryptophan ketoglutarate solution in clinical pancreas transplantation
    A Agarwal
    Department of Surgery, Indiana University School of Medicine, 550 N. University Boulevard #4258, Indianapolis, IN 46202, USA
    Transplant Proc 37:3523-6. 2005
    ..Serum fasting blood glucose and serial amylase remained comparable at all intervals posttransplantation. Within this range of cold ischemia time, HTK appears to provide effective pancreas preservation...
  25. ncbi Elimination of false-positive Histoplasma antigenemia caused by human anti-rabbit antibodies in the second-generation Histoplasma antigen assay
    L J Wheat
    MiraVista Diagnostics, Indianapolis, Indiana 46241, USA
    Transpl Infect Dis 8:219-21. 2006
    ..Physicians should be aware of the potential for false-positive results in sandwich immunoassays in specimens from patients who have received RATG...
  26. ncbi Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation
    G L Bumgardner
    Division of Transplantation, Department of Surgery, The Ohio State University and Medical Center, Columbus, Ohio 43210-1250, USA
    Transplantation 72:839-45. 2001
    ..There was no beneficial effect of daclizumab on graft survival at 3 years, but the trial was inadequately powered to detect this. Both studies showed excellent graft and patient survival at 3 years...
  27. ncbi Safety profile, pharmacokinetics, and pharmacodynamics of siplizumab, a humanized anti-CD2 monoclonal antibody, in renal allograft recipients
    T L Pruett
    University of Virginia Health Systems, Department of Surgery, Charlottesville, Virginia, USA
    Transplant Proc 41:3655-61. 2009
    ....
  28. ncbi Improved cyclosporine pharmacokinetics in maintenance renal transplant recipients converted to cyclosporine for microemulsion
    M D Pescovitz
    Department of Surgery, Indiana University, Indianapolis, IN 46202 5250, USA
    Transpl Int 11:S94-7. 1998
    ..We tested the hypothesis that a cyclosporine microemulsion (CsA-ME) would result in reduced variability in stable maintenance renal transplant patients when compared with the original formulation of cyclosporine (CsA)...
  29. ncbi Simultaneous liver and pancreas transplantation in patients with cystic fibrosis
    J A Fridell
    Department of Surgery, Indiana University, 550 N University Boulevard 4258, Indianapolis, IN 46202, USA
    Transplant Proc 37:3567-9. 2005
    ..Liver transplantation is the treatment of choice for cirrhosis in this setting, but the addition of an isolated simultaneous pancreas transplant in patients with CFRD has not been reported...
  30. ncbi New crossmatch technique eliminates interference by humanized and chimeric monoclonal antibodies
    B K Book
    Department of Surgery, Indiana University, Indianapolis, Indiana 46202, USA
    Transplant Proc 37:640-2. 2005
    ..1 microg/mL, but gave false positive B-cell FCXM and CDCXM with some samples. No interference by DAC occurred using TMS. TMS may be useful to differentiate de novo donor-specific Ab after treatment with humanized or chimeric Ab...
  31. ncbi Pharmacokinetics of neoral in stable renal transplant recipients with long-term diabetes mellitus
    C Deel
    Division of Nephrology and Department of Surgery and Microbiology Immunology, Indiana University Medical Center, Indianapolis, IN 46202, USA
    Transplant Proc 39:109-14. 2007
    ..Because of very high intrapatient variability in this group of patients, C2 levels may not be reliable for TDM of Neoral despite high correlation with AUC(0-8h). C4 level may be a valid alternative for these patients...
  32. ncbi Benefits of cytomegalovirus prophylaxis in solid organ transplantation
    Mark D Pescovitz
    Department of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202
    Transplantation 82:S4-8. 2006
    ....
  33. ncbi Immunosuppression in pediatric solid organ transplantation
    Avinash Agarwal
    Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Semin Pediatr Surg 15:142-52. 2006
    ..Future studies will determine the best way to assess the functional immune status of a pediatric transplant recipient to maintain the fine balance and avoid the complications of either excessive or inadequate immunosuppression...
  34. ncbi Steroid withdrawal for pancreas after kidney transplantation in recipients on maintenance prednisone immunosuppression
    Jonathan A Fridell
    Department of Surgery, Indiana University School of Medicine, Indianapolis, 46202, USA
    Transplantation 82:389-92. 2006
    ....
  35. ncbi Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review
    Robert P Nelson
    Division of Hematology Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    J Clin Neuromuscul Dis 10:170-7. 2009
    ..Rituximab, a monoclonal antibody specific for CD20, is used primarily to treat B-cell non-Hodgkin lymphoma. Although it has been used for treatment of a number of autoimmune diseases, there is limited experience in MG...
  36. ncbi Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses
    Avinash Agarwal
    Department of Surgery, Indiana University, Indianapolis, IN, USA
    Am J Transplant 4:1357-60. 2004
    ..5 pg/mL). There was no decline in T-cell proliferation in response to phytohemagglutinin or allogeneic lymphocyte stimuli. Stimulation indices in the presence of both concentrations of tetanus toxoid rose significantly at 4 weeks...
  37. ncbi Ipsilateral placement of simultaneous pancreas and kidney allografts
    Jonathan A Fridell
    Department of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Transplantation 78:1074-6. 2004
    ..The placement of the pancreas and kidney transplants on the same side is safe and does not compromise patient or graft survival. This approach preserves the left iliac system for future retransplantation if necessary...
  38. ncbi In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody
    Richard A Sidner
    Indiana University School of Medicine, Department of Surgery, Indianapolis, IN 46202, USA
    Hum Antibodies 13:55-62. 2004
    ..001) after treatment. We conclude that single dose rituximab ablates B cells in high PRA dialysis patients awaiting transplantation. B-cell ablation, particularly memory B cells, was long-lasting, lagging repopulation by CD5(+) B cells...
  39. ncbi Comparison of histidine-tryptophan-ketoglutarate solution and University of Wisconsin solution for organ preservation in clinical pancreas transplantation
    Jonathan A Fridell
    Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Transplantation 77:1304-6. 2004
    ..This study assesses the efficacy of histidine-tryptophan-ketoglutarate (HTK) compared with UW in pancreas transplantation...
  40. ncbi False-positive Histoplasma antigenemia caused by antithymocyte globulin antibodies
    L J Wheat
    Mira Vista Diagnostics, 4444 Decatur Boulevard, Suite 300, Indianapolis, IN 46241, USA
    Transpl Infect Dis 6:23-7. 2004
    ..False antigenemia peaked at 2-4 weeks after ATG administration and cleared over the next few months. Physicians should be aware of the potential for false-positive results in specimens from patients who have received ATG...
  41. ncbi Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174
    Christopher M Bearden
    Department of Surgery, Indiana University, Indianapolis, IN, USA
    Am J Transplant 5:50-7. 2005
    ..RIT decreases antibody production and isotype switching to neoantigens and might be useful to prevent antibody response to therapeutic drugs and to newly transplanted organs...
  42. ncbi Rituximab, B-lymphocyte depletion, and preservation of beta-cell function
    Mark D Pescovitz
    Indiana University School of Medicine, Indianapolis, USA
    N Engl J Med 361:2143-52. 2009
    ..It is possible to achieve selective depletion of B lymphocytes with rituximab, an anti-CD20 monoclonal antibody. This phase 2 study evaluated the role of B-lymphocyte depletion in patients with type 1 diabetes...
  43. ncbi Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics
    Carlos A Vieira
    Department of Surgery, Indiana University, Indianapolis, IN, USA
    Transplantation 77:542-8. 2004
    ..CONCLUSIONS: RTX can be safely administered and may be an effective agent to reduce high-titer anti-HLA Abs in subjects awaiting kidney transplantation...
  44. ncbi Effect of calcineurin inhibitors on posaconazole blood levels as measured by the MVista microbiological assay
    David Zhuang
    MiraVista Diagnostics and MiraBella Technologies, Indianapolis, IN 46241, USA
    Antimicrob Agents Chemother 52:730-1. 2008
    ..No effect was observed. However, concurrent or recently discontinued treatment with other antifungal drugs caused false-positive results, emphasizing a limitation of microbiological assays for antifungal drug level measurement...
  45. ncbi Comparison of histidine-tryptophan ketoglutarate and University of Wisconsin solutions as primary preservation in renal allografts undergoing pulsatile perfusion
    A Agarwal
    Department of Surgery, Indiana University School of Medicine, 550 N. University Boulevard #4258, Indianapolis, IN 46202, USA
    Transplant Proc 37:2016-9. 2005
    ..005). CONCLUSION: UW and HTK appear to have similar efficacy in kidney preservation with pulsatile perfusion. HTK preservation solution can be used safely in conjunction with pulsatile preservation for cold storage of renal allografts...
  46. ncbi Evaluation of posttransplant RhD sensitization in RhD-negative renal recipients
    B K Book
    Indiana University School of Medicine, Department of Surgery, Indianapolis, Indianapolis 46202, USA
    Transplant Proc 34:3140-1. 2002
  47. ncbi Pronase treatment facilitates alloantibody flow cytometric and cytotoxic crossmatching in the presence of rituximab
    Christopher M Bearden
    Department of Surgery, Indiana University, Indianapolis, IN, USA
    Hum Immunol 65:803-9. 2004
    ..In addition, there was no change in the crossmatches of pooled high panel reactive antibody (PRA) sera after pronase treatment. RIT could be used without worry about losing the ability to perform transplant immunologic monitoring...
  48. ncbi Use of the end-to-end anastomotic circular stapler for creation of the duodenoenterostomy for enteric drainage of the pancreas allograft [corrected]
    Jonathan A Fridell
    Department of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    J Am Coll Surg 198:495-7. 2004
  49. ncbi Removal of therapeutic anti-lymphocyte antibodies from human sera prior to anti-human leukocyte antibody testing
    Christopher M Bearden
    Department of Surgery, Indiana University, Indianapolis, IN 46202, USA
    J Immunol Methods 300:192-9. 2005
    ..103, 0.309 for ATGAM, 0.199 for Thymo, and 12.1 for rituximab. ALAs can be effectively removed from serum by the use of magnetic beads conjugated with Ab specific for ALA thereby permitting immunologic monitoring without interference...
  50. ncbi Utility of HbA1c in the detection of subclinical post renal transplant diabetes
    Rebecca Hoban
    Department of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Transplantation 81:379-83. 2006
    ..1% of all patients and 19.4% of blacks found to have an elevated HbA1c. HbA1c testing should be considered as a screening test for PTDM, especially in African Americans...
  51. ncbi Internal hernia after pancreas transplantation with enteric drainage: an unusual cause of small bowel obstruction
    Avinash Agarwal
    Department of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Transplantation 80:149-52. 2005
    ..Prompt detection of small bowel obstruction with early surgical intervention can minimize complications and preserve allograft function...
  52. ncbi Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients
    Guy Boivin
    Research Center in Infectious Diseases, Centre Hospitalier Universitaire de Quebec and Laval University, Quebec City, Canada
    J Infect Dis 189:1615-8. 2004
    ..Valganciclovir was associated with negligible risk of resistance and thus constitutes a useful alternative to ganciclovir prophylaxis for CMV in high-risk SOT recipients...
  53. ncbi Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients
    Atul Humar
    University Health Network, Toronto General Hospital, Toronto ON, Canada
    Am J Transplant 4:644-9. 2004
    ..Similarly, single time point measures at the end of prophylaxis or month 4 had low sensitivity for disease prediction. Overall, regular CMV plasma viral load measurements were only of modest value in predicting CMV disease...
  54. ncbi Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients
    Carlos Paya
    Mayo Clinic, Rochester, MN, USA
    Am J Transplant 4:611-20. 2004
    ..2%, vs 3.2% ganciclovir) the safety profile was similar for both drugs. Overall, once-daily oral valganciclovir was as clinically effective and well-tolerated as oral ganciclovir tid for CMV prevention in high-risk SOT recipients...
  55. ncbi Prevention and treatment of cytomegalovirus disease in solid organ transplant recipients: the clinical and economic impact of evolving strategies. Introduction
    Mark D Pescovitz
    Am J Health Syst Pharm 60:S3-4. 2003
  56. ncbi A surveillance study of adenovirus infection in adult solid organ transplant recipients
    Atul Humar
    University of Toronto, Toronto, Ontario, Canada
    Am J Transplant 5:2555-9. 2005
    ..No serious clinical sequelae or effects on subsequent acute rejection were observed...
  57. ncbi Review of the CMV in renal transplantation
    Mark D Pescovitz
    Saudi J Kidney Dis Transpl 18:505-11. 2007
  58. ncbi Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients
    Reinier M van Hest
    Department of Hospital Pharmacy, Erasmus MC, Rotterdam, The Netherlands
    J Am Soc Nephrol 17:871-80. 2006
    ..Patients in whom cyclosporine and mycophenolate mofetil are combined may need higher mycophenolate mofetil doses, especially during the early phase after transplantation than currently recommended for optimal MPA exposure...
  59. ncbi Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients
    Hugh Wiltshire
    Roche Products, Welwyn Garden City, Herts, UK
    Transplantation 79:1477-83. 2005
    ..CONCLUSIONS: The greater systemic exposure to ganciclovir delivered by valganciclovir was associated with delayed development of viremia. There was only a weak association between AUC and hematological toxicity...
  60. ncbi Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients
    Hugh Wiltshire
    Roche Products Ltd, Welwyn Garden City, UK
    Clin Pharmacokinet 44:495-507. 2005
    ..This indicates that oral valganciclovir is suitable in circumstances requiring prophylactic use of ganciclovir and allows for more convenient management of patients at risk of CMV disease...
  61. ncbi Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients
    Atul Humar
    University of Toronto, Toronto, Ontario, Canada
    Am J Transplant 5:1065-70. 2005
    ..002). In D+/R- patients, CMV serology testing is for the most part not clinically useful for predicting subsequent disease. However, seroconversion by 6 months may be useful for identifying patients at risk of late-onset CMV disease...
  62. ncbi Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients
    Richard B Freeman
    New England Medical Center of Transplant Surgery, Boston, MA 2 Mayo Clinic, Rochester, MN 02111, USA
    Transplantation 78:1765-73. 2004
    ..Cytomegalovirus (CMV) D+/R- solid-organ transplant (SOT) recipients carry increased risk of developing CMV disease; however, other risk factors in these patients have not been delineated...
  63. ncbi Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation
    Helio Tedesco-Silva
    Setor de Transplante Renal, Hospital do Rim Hipertensão UNIFESP, Rua Borges, Lagoa, 960 11o andar, Sao Paulo, SP, Brazil
    Transplantation 82:1689-97. 2006
    ..Phase II trials of FTY720, a novel immunomodulator, have shown promise in preventing rejection with both standard and reduced cyclosporine exposure. This study was designed to confirm those findings...
  64. ncbi Is low-dose valganciclovir the same as appropriate-dose valganciclovir?
    Mark D Pescovitz
    Transplantation 84:126; author reply 126-7. 2007
  65. ncbi Presensitization: the problem and its management
    Stanley C Jordan
    Transplant Immunology Laboratory, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90048, USA
    Clin J Am Soc Nephrol 1:421-32. 2006
    ..Despite the great interest in the problem of allosensitization, with one notable exception, there is a major deficiency in controlled clinical trials, the conduct of which should be a focus for the near future...
  66. ncbi Pancreas after kidney transplantation
    Sundaram Hariharan
    Division of Nephrology, Medical College of Wisconsin, 9200 W. Wisconsin Avenue, Milwaukee, WI 53226, USA
    J Am Soc Nephrol 13:1109-18. 2002
  67. ncbi Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment
    Mark D Pescovitz
    N Engl J Med 354:1961-3. 2006